Physician profile
Cain Ranjan
NPI 1750487336
$7,826.39
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $1,179 · 2021: $2,193 · 2022: $1,719 · 2023: $1,101 · 2024: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.49 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,759.21 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $1,242.83 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.94 | 2019-2023 | Stiolto Respimat, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $615.04 | 2019-2023 | Farxiga |
| Pfizer INC. | $531.38 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.21 | 2019-2022 | |
| Astellas Pharma US INC | $373.84 | 2020-2023 | |
| Glaxosmithkline, LLC. | $343.98 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $285.77 | 2019-2023 | Eliquis |
| Allergan, INC. | $199.37 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.51 | 2024 | Lifevest |
| Orexo US, INC. | $161.39 | 2019-2023 | Zubsolv |
| Amarin Pharma, INC. | $141.44 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.86 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $104.12 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $98.36 | 2021-2023 | Sublocade |
| Ironwood Pharmaceuticals, INC | $94.41 | 2020-2021 | |
| Lilly USA, LLC | $82.35 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $74.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $73.00 | 2022 | |
| Amgen INC. | $57.62 | 2020-2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $54.91 | 2019-2021 | |
| Daiichi Sankyo INC. | $40.32 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $32.75 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $30.10 | 2020 | |
| Almatica Pharma LLC | $21.12 | 2023 | Gralise, Loreev Xr |
| Exact Sciences Corporation | $19.50 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.75 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cain Ranjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.